1

- 1 Prevalence of Hyperglycemia in Pregnancy using early, standard and late screening: a
- 2 study in the Primary Care Health in Lima, Peru
- 3
- 4 Authors
- 5
- 6 S.N. Seclén¹ (ORCID: 0000-0002-2431-099X)
- 7 Lucy Nelly Damas-Casani² (ORCID : 0000-0002-8714-2217)
- 8 Vicky Delia Cecilia Motta-Montoya¹
- 9 Sandra Lesly Jiménez-Martel^{1,3}
- 10 Marlon Yovera-Aldana ⁴. (ORCID: 0000-0002-1947-7736)
- 11
- 12 Affiliations
- 13 1 Universidad Peruana Cayetano Heredia, Lima, Perú
- 14 2 Endocrinology Service, Hospital María Auxiliadora, Lima, Perú
- 15 3 Endocrinology Service, Hospital Santa Rosa, Lima, Perú
- 16 4 Grupo de Investigación de Neurociencias, Metabolismo y Efectividad clínica y
- 17 Sanitaria, Universidad Científica del Sur, Lima, Perú

18

19 Corresponding author

20 E-mail: <u>myovera@cientifica.edu.pe</u> (MYA)

2

21 Abstract

Objective: To determine the prevalence of hyperglycemia in pregnancy (HIP) based onthe timing of screening in pregnant women.

Materials and Methods: A cross-sectional study was conducted on pregnant women 24 recruited from February 2019 to August 2022 in four primary care centers in Lima, 25 26 excluding those with known diabetes. Screening involved an Oral Glucose Tolerance Test with 75 g of glucose at the first contact. It was classified as early if performed before 24 27 28 weeks, standard between 24-28 weeks, and late if after 29 weeks. For gestational diabetes mellitus (GDM), we used the IADPSG diagnostic criteria for any gestational age. For 29 30 diabetes in pregnancy (DIP), glucose levels over 126 mg/dl fasting or over 200 mg/dl at 31 2 hours post-load were used. We calculated prevalence ratios for GDM and DIP based on the type of screening. 32

Results: We included 4,495 pregnant women with an average age of 29 years. The
prevalence of HIP was 14.9%, GDM was 14.2%, and DIP was 0.7%. Early GDM
screening showed a 23% higher prevalence compared to GDM screening at 24-28 weeks,
adjusted for age (PR 1.23; 95% CI 1.01 – 1.49; p=0.036). No differences were found for
DIP across screening types.

38 Conclusion: In pregnant women at four primary centers in Lima, one in seven pregnant 39 women (14.9%) had HIP, GDM was 14.2%, and DIP was 0.7%.. Early screening showed 40 the highest proportion of GDM compared to standard or late screening. Longitudinal 41 studies are needed to validate whether this higher early prevalence impacts maternal-42 perinatal complications.

Key words (MeSH) : Diabetes, gestacional; mass screening; prevalence study; glucose
tolerance test; Peru;

Introducción 45

Globally, approximately 16.7% of pregnancies present hyperglycemia in pregnancy 46 (HIE), defined as any known pre-existing alteration or first diagnosed during gestation. 47 Of these cases, 80.3% are due to gestational diabetes mellitus (GDM). The prevalence of 48 HIE progressively increases with age and 80% originating in low- to middle-income 49 countries where access to healthcare is limited. [1] HIE is associated with maternal and 50 51 perinatal complications. [2] Normalizing blood glucose levels in patients with GDM and diabetes in pregnancy (DIP) through lifestyle changes, and in some cases 52 53 pharmacological treatment, has been shown to reduce maternal-perinatal complications by more than 60%. [3] 54

55 In the last two decades, the increase in the prevalence of GDM has ranged from 16% to 127%. This is attributed to the progressive rise in obesity by unhealthy lifestyles, greater 56 57 governmental efforts to conduct universal screening and a diagnostic threshold criteria diminished[4]. In Peru, the prevalence of overweight and obesity in women of 58 reproductive age is 37% and 28%, respectively[5]. Consequently, nearly 50% of pregnant 59 women have excess weight in the first trimester, making it one of the main risk factors 60 for the development of GDM. [6] Moreover, the new International Association of the 61 62 Diabetes and Pregnancy Study Groups (IADPSG) criteria, have increased the frequency of GDM by as much as 6 to 11 times [7]. Howewer, the diagnosis and treatment are 63 cost-effective when considering postpartum outcomes for both the mother and the child. 64 [8-10]. The International Federation of Gynecology and Obstetrics (IFGO) proposes 65 different strategies to implement universal screening depending on the resources 66 available in each country. Standard screening in the first trimester includes only fasting 67 glucose; however, it suggests that in high-risk populations, an oral glucose tolerance test 68

4

69 (OGTT) with 75 g could be performed at the initial visit, repeating it at 24-28 weeks if
70 the first result is negative. [11] Thus, waiting until that gestational age to initiate treatment
71 could delay a potential improvement in the rate of complications, similar to the preventive
72 action of acetylsalicylic acid to prevent preeclampsia. [12]

Recent studies suggest that abnormal, non-diabetic fasting glucose values in early 73 screening impact complications. [13] Both early hyperglycemia and DIP are associated 74 with worse outcomes than GDM diagnosed by standard methods. [14,15] On the other 75 hand, treating GDM identified by IADPSG criteria using OGTT before 22 weeks in 76 pregnant women with at least one risk factor for GDM, has been shown to reduce neonatal 77 outcomes, although it does not affect those related to hypertensive disorders. [16] 78 However, despite the diversity of criteria for GDM, there is no consensus on first-79 trimester hyperglycemia, with its nomenclature being variable and complicating 80 comparison between regions. [17] 81

In Lima-Peru, a study conducted in a reference center using universal screening between 24-28 weeks with IADPSG criteria found a prevalence of 16%. [18] This prevalence, which is close to the global average, could differ if evaluated in primary care health facilities, especially if early OGTT (before 24 weeks) is applied. Therefore, the objective of this study is to determine the prevalence of hyperglycemia during pregnancy in four primary care centers in South Lima at the first contact using OGTT.

Matherial and Methods 88

Study Design and clinical setting 89

90 A cross-sectional study was conducted analyzing data from the Gestational Education in Diabetes (GEIDI) program implemented in four maternal and child health centers in 91 South Lima. The GEIDI program is an early diagnosis and educational intervention 92 93 strategy aimed at pregnant women diagnosed with gestational diabetes through the oral glucose tolerance test (OGTT) during their initial contact. This program was funded by 94 the World Diabetes Foundation (WDF) and executed by a professional and technical team 95 from the Peruvian Juvenile Diabetes Association (ADJ in Spanish) and the María 96 Auxiliadora Hospital. Interventions were carried out at the José Carlos Mariátegui 97 98 Maternal and Child Center (JCM) in Villa María del Triunfo district, San Genaro Maternal and Child Center (SG) and the Virgen del Carmen Maternal and Child Center 99 (VC) in Chorrillos district and Manuel Barreto Maternal and Child Center (MB) in San 100 101 Juan de Miraflores district. Pregnant women were recruited from February 2019 to 102 August 2022.

Population, sample and sampling 103

Pregnant women attended at the four primary care centers, aged 15 years or older, Peruvian 104 105 nationality, and having resided in the district for more than six months, were included in the study. Fasting glucose screening is part of the procedures of the Ministry of Health in 106 maternal care, but it was applied for the first time in this population through the oral glucose 107 108 tolerance test (OGTT) using 75 gr of glucose. Patients with known diabetes mellitus prior to pregnancy, uncertain last menstrual period or not confirmed by ultrasound performed 109 before 24 weeks of gestation, and multiple pregnancies were excluded. The sampling 110

6

method was non-probabilistic census, accepting all pregnant women who met the eligibilitycriteria based on the provided data.

113 Variables

Hyperglycemia in Pregnancy: For this study, diabetes in pregnancy was defined as having fasting glucose values greater than 126 mg/dl (7.0 mmol/l) or values greater than 200 mg/dl (11.1 mmol/l) at 2 hours, at any gestational age. For gestational diabetes mellitus (GDM), we applied the HAPO criteria, where a diagnosis was positive if fasting glucose was between 92 and 125 mg/dl (5.1 to 6.9 mmol/l), glucose at 1 hour was greater than 180 mg/dl (9.9 mmol/l), and glucose at 2 hours was between 153 and 199 mg/dl (8.5 to 11.0 mmol/l), with at least one positive result being sufficient.

Other Variables: Based on the gestational age during the OGTT, the timing of screening was classified as early (24 weeks or less), standard (24-28 weeks), and late (more than 28 weeks). The year of the OGTT (2019, 2020, 2021, 2022) and age group (less than 18; 18 to 24.9; 25 to 29.9; 30 to 34.9; 35 to 39.9; 40 to 44.9; and 45 or more) were also recorded.

125 **Procedures**

The GEIDI program scheduled an Oral Glucose Tolerance Test with 75 g of anhydrous 126 glucose during the first contact of the pregnant woman with the health center, obtaining 127 three venous samples: baseline, at 1 hour, and at 2 hours. Glucose was measured using 128 the glucose oxidase method, employing a Wiener reagent with a coefficient of variation 129 <2%, following standard guidelines for analysis. An online reporting system was 130 established for laboratory results registration. After diagnosis, clinical management was 131 132 based on the guidelines from the Ministry of Health. Additionally, educational sessions were provided for nutritional management and tools for glycemic self-monitoring were 133

7

supplied through the donation of glucose meters. Pregnant women were referred to the
Hospital María Auxiliadora for evaluation by endocrinology and gynecology if the
maternal-infant health centers lacked the necessary specialty or if the patient required
evaluation at a higher-level facility.

For the study, the authors' team requested the laboratory results data of the screened pregnant women from the GEIDI program coordinators. This information was provided without identifying data such as names or national identity document numbers. Data were evaluated and analyzed from January 15 to March 30, 2024 and included age, date of the OGTT, gestational age, source health center, and the glucose values from the OGTT.

143 Analysis plan

The health center of origin, age group, gestational age at the time of the oral glucose tolerance test (OGTT), and the type of screening performed were described using absolute and relative frequencies. Additionally, the proportion of altered glycemia, the total number of glucose measurements, and the type of glycemic alteration were calculated. The demographic characteristics of pregnant women were compared based on the timing of screening: early (less than 24 weeks), standard (24-28 weeks), and late (more than 28 weeks).

151 Crude and age-adjusted prevalence ratios for the occurrence of GDM or diabetes in 152 pregnancy (DIP) were calculated according to the screening strategy using Poisson 153 regression with robust variances. By the same method, the prevalence ratio for GDM or 154 DIP by age group and year of diagnosis was also calculated. Statistical analysis was 155 performed using Stata version 18.1 (Stata Corp, College Station, Texas, USA), with a 156 significance level set at 0.05 for all hypothesis tests.

Ethical considerations 157

- This protocol was evaluated by the Ethics Committee of the Universidad Peruana 158
- Cayetano Heredia, with registration code 200797 and certificate 646-01-21. Patient 159
- 160 confidentiality was maintained through the anonymization of records..

Results 161

The study was conducted from February 2019 to August 2022, with a total of 4,710 162 163 pregnant women screened. 4,495 met the inclusion and exclusion criteria. From the selected group, 2,590 (57.6%) underwent early screening, 901 (20.0%) standard 164 screening, and 1,004 (22.4%) late screening (Figure 1). The restrictions imposed in 2020 165 166 due to the COVID-19 pandemic led to a decrease in the screening rate; however, this rate recovered in 2021 and 2022. 167

168

Figure 1. Selection flowchart of the GEIDI Program for the calculation of the 169 prevalence of gestational diabetes mellitus 170

- 171 OGTT: Oral Glucose Tolerance Test. DM: Diabetes mellitus
- 172

General Characteristics 173

The screened pregnant population was predominantly young, with 78.1% between 18 and 174 175 35 years. Regarding OGTT results, abnormal fasting glucose levels were found in 539 pregnant women (12.0%), representing the highest percentage of altered results. 176 Abnormal glucose levels at 1 hour were identified in 193 women (4.2%), and abnormal 177 glucose levels at 2 hours were found in 97 women (2.1%)178 Breaking down these findings, it was observed that among the screened pregnant 179 population, only 542 (12.1%) exhibited altered fasting glucose levels, either in isolation 180 181 or in combination with postprandial glucose levels, and only 127 (2.8%) showed 182 alterations in postprandial glucose levels (Table 1).

184

185 Table 1. Characteristics of pregnant women screened

186

Characterstics N (%) 4495 (100.0) Total Age (years) Media DE < 18 121 (2.7) 18 - 24.91319 (29.3) 25 - 29.9 1245 (27.7) 30 - 34.9950 (21.1) 35 - 39.9 627 (13.9) 40 - 44.9213 (4.7) 45 and over 20 (0.4) Health care facility Jose Carlos Mariátegui VMT 2400 (53.4) Manuel Barreto SJM 343 (7.6) San Genaro - Chorrillos 1233 (27.4) Virgen del Carmen - Chorrillos 519 (11.6) Screening year 2019 1953 (43.5) 2020 657 (14.6) 2021 1298 (28.9) 2022 587 (13.1) Screening gestational age 8 or less 477 (10.6) 9 a 12 723 (16.1) 13 a 16 559 (12.4) 17 a 23 831 (18.5) 24 a 28 898 (19.9) 29 a 32 492 (10.9)

Screening time Early

Standard

Late

37 and over

32 a 36

413 (9.2)

102 (2.3)

2590 (57.6)

898 (20.0)

1007 (22.4)

Blood glucose	
Fasting glucose	
Less than 92 mg/dl(5.1 mmol/l)	3956 (88.0)
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	520 (11.6)
126 and over (7 mmol/l)	19 (0.4)
Blood glucose at 1 hour	
Less than 180 mg/dl (9.9 mmol/l)	4302 (95.7)
180 and over (10 mmol/l)	193 (4.3)
Blood glucose at 2 hours	
Less than 153 (8.5 mmol/l)	4398 (97.8)
153 to 199.9 mg/dl (8.5 to 11.0 mmol/L)	74 (1.7)
200 and over (11.1 mmol/l)	23 (0.5)
Type of glycemic alteration	
No	3826 (85.1)
Basal only	441 (9.8)
Basal and postprandial	101 (2.3)
Postprandial only(s)	127 (2.8)

187

The pregnant women included in the three screening strategies had comparable ages 188 189 (p=0.213). The early screening strategy exhibited the highest proportion of altered fasting glucose, with 13.5%, compared to 9.9% in the standard screening and 9.8% in the late 190 screening (p=0.010) (Table 2). 191

192

Table 2. Demographic characteristics according to screening strategy in pregnant 193

- 194 women.
- 195

	Early screening	Standard	Late screening	p-value
		screening		
General	2590	898	1007	
Age (years)				
(Media ± SD)	28.3 ± 6.6	28.1 ± 6.6	28.0 ± 6.4	0.310 ª
Age group				

< 18	80 (3.1)	15 (1.7)	26 (2.6)	
18 – 24.9	717 (27.7)	291 (32.4)	311 (30.9)	
25 - 29.9	752 (29.0)	244 (27.2)	249 (24.7)	
30 - 34.9	529 (20.4)	169 (18.8)	252 (25.0)	
35 - 39.9	368 (14.2)	129 (14.4)	130 (12.9)	
40 - 44.9	129 (5.0)	46 (5.1)	38 (3.8)	
45 and over	15 (0.6)	4 (0.5)	1 (0.1)	
Health care facility, n(%)				
Jose Carlos Mariátegui VMT	675 (26.1)	344 (38.3)	214 (21.3)	<0.001 a
Manuel Barreto SJM	1437 (55.5)	362 (40.3)	601 (59.7)	
San Genaro – Chorrilos	270 (10.4)	125 (13.9)	124 (12.3)	
Virgen del Carmen –Chorrillos	208 (8.0)	67 (7.5)	68 (6.8)	
Screening year, n(%)				
2019	1140 (44.0)	385 (42.9)	428 (42.5)	<0.001 a
2020	407 (15.7)	132 (14.7)	118 (11.7)	
2021	668 (25.8)	284 (31.6)	346 (34.4)	
2022	375 (14.5)	97 (10.8)	115 (11.4)	
Fasting glucose , (Media \pm SD)				
mg/dl	80.5 ± 13.1	78.5 ± 10.0	77.7 ± 11.3	<0.001 a
mmol /l	4.51 ± 0.73	4.36 ± 0.56	4.31 ± 0.63	
Blood glucose at 1 hour (Media ± SD)				
mg/dl	120 ± 32.8	119.3 ± 29.9	121.9 ± 29.8	0.161 ª
mmol /l	6.66 ± 1.82	6.62 ± 1.66	6.77 ± 1.65	
Blood glucose at 2 hours (Media ± SD)				
mg/dl	96.1 ± 24.7	96.7 ± 23.2	95.7 ± 22.7	0.646 ª
mmol /l	5.33 ± 1.37	5.37 ± 1.29	5.31 ± 1.266	
Fasting glucose category, n (%)				
Less than 92 mg/dl (5.1 mmol/l)	2239 (86.5)	809 (90.1)	908 (90.2)	0.005 °
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	337 (13.0)	86 (9.6)	97 (9.6)	
126 mg /dl and over (7 mmol/l)	14 (0.5)	3 (0.3)	2 (0.2)	
Blood glucose at 1 hour category, n (%)				
Less than 180 mg/dl (9.9 mmol/l)	2481 (95.8)	857 (95.0)	964 (96.1)	0.901 ^b
180 mg/dl and over (10 mmol/l)	109 (4.2)	41 (4.6)	43 (4.3)	
Blood glucose at 2 hours category, n (%)				
Less than 153 mg/dl (8.5 mmol/l)	2534 (97.8)	874 (97.3)	990 (98.3)	0.338 °
153 to 199.9 mg/dl (8.5 to 11.0	40 (1.5)	21 (2.3)	13 (1.3)	
mmol/L)				

13

200 mg/dl and over (11.1 mmol/l)	16 (0.6)	3 (0.3)	4 (0.4)	
pe of glycemic alteration, n (%)				
No	2167 (83.7)	779 (86.6)	880 (87.4)	0.007 b
Basal only	294 (11.4)	69 (7.7)	78 (7.8)	
Basal and postprandial	60 (2.3)	20 (2.2)	21 (2.1)	
Postprandial only(s)	69 (2.7)	30 (3.3)	28 (2.8)	

196

197 VMT villa María del Triunfo. SJM: San Juan de Miraflores a Anova One way b Pearson chi square test c Fisher exact test

198

Prevalence of Hyperglycemia in Pregnancy 199

A general prevalence of hyperglycemia in pregnancy was found to be 14.9% (95% CI 200 13.9 -15.9), with gestational diabetes mellitus (GDM) at 14.2% (95% CI 13.2 - 15.3) and 201 202 diabetes in pregnancy at 0.7% (95% CI 0.5 - 0.9). Of these cases, 95.5% corresponded to GDM (60.2% identified before 24 weeks and 35.3% after 24 weeks), while 4.5% 203 presented with diabetes in pregnancy (Table 3). 204

205

Table 3. Prevalence of hyperglycemia in pregnancy of screened pregnant women 206

in four centers in South Lima. 207

Tipo de hiperglicemia en embarazo	Prevalence ^a	CI 95%	Prevalence ^b	CI 95%
	n (%)		%	
No	3826 (85.1)			
Hiperglicemy in pregnancy	669 (14.9)	(IC95% 13.9 -15.9)	100%	
Gestational diabetes	639 (14.2)	(IC95% 13.2 – 15.3)	95.5%	(IC95% 93.7 – 96.9)
Early GDM	403 (8.9)	(IC95% 8.1 – 9.8)	60.2%	(IC95% 56.4 – 63.9t)
Standard GDM	113 (2.5)	(IC95% 2.1 – 3.0)	16.9%	(IC95% 14.1 -19.9))
Late GDM	123 (2.7)	(IC95% 2.2 – 3.2)	18.4%	(IC95% 15.5 – 21.5)
Diabetes in pregnancy	30 (0.7)	(IC95% 0.5 - 0.9).	4.5%	(IC95% 3.0 – 6.3)
Early DIP	20 (0.4)	(IC95% 0.2 – 0.6)	3.0%	(IC95% 1.8 – 4.5)
Standard DIP	6 (0.1)	(IC95% 0.05 – 0.3)	0.9%	(IC95% 0.3 – 1.9)
Late DIP	4 (0.1)	(IC95% 0.02 – 0.2)	0.6%	(IC95% 0.1 – 1.5)

GDM: Gestational diabetes DIP: Diabetes n pregnancy 208

14

209 ^a taking as a denominator the total of 4495 pregnant women. ^b Taking as a denominator the totality of 669 pregnant women with

210 HIP

According to the timing of the screening, early showed a higher frequency of gestational 211

- diabetes at 26%, compared to standard x(PR 1.26; 95% CI 1.01 1.51; p=0.035) (Table 212
- 4). Tables S2 and S3 provide a description of the patients with GDM and DIP, 213
- 214 respectively.

215 Table 4. Prevalence ratios of glycemic results according to type of screening

	n /N	Prevalence (CI 95%)	Crude	p-value	Ajusted*	p-value
Gestational diabetes						
Early screening ^a	403 / 2570	15.7 (14.3 – 17.1)	1.23 (1.01 -1.50)	0.031	1.23 (1.01 – 1.49)	0.036
Standard screening ^b	113 / 892	12.7 (10.6 - 15.0)	1.00		1.00	
Late screening ^c	123 / 1003	12.3 (10.3 – 14.5)	0.96 (0.76 – 1.22)	0.790	0.97 (0.76 - 1.23)	0.820
Diabetes in pregnancy						
Early screening ^a	20/2590	0.77 (0.47 - 1.19)	1.15 (0.46 – 2.86)	0.755	1.13 (0.46 – 2.80)	0.790
Standard screening ^b	6 / 898	0.67 (0.25 - 1.45)	1.00		1.00	
Late screening ^c	4 /1007	0.39 (0.11 – 1.01)	0.59 (0.17 – 2.10)	0.419	0.62 (0.17 – 2.23)	0.474

216 PRc: Crude prevalence ratio. RPa: Adjusted prevalence ratio.

217 * Age adjusted. a Before 24 weeks. b Between 24 -28 weeks. c After 28 weeks

218

219

Hyperglycemia before 24 weeks 220

When the OGTT was performed before 24 weeks (early screening), the prevalence of 221

GDM in 2020 showed a decrease of 34% compared to 2019. Subsequently increased a 222

45% in 2021 and a 92% in 2022. Regarding diabetes in pregnancy (DIP), no significant 223

differences were observed among the years. Additionally, 224

225 A progressive increase in GDM was evident with advancing age, starting from 30 years.

This trend was statistically significant only in the age group of 30 to 40 years (Table 5). 226

Hyperglycemia after 24 weeks 228

For the OGTT conducted between 24 and 28 weeks (standard screening), the prevalence 229 of GDM decreased in 2020, followed by increases of 24% and an astonishing 102% in 230 231 2021 and 2022, respectively. On the other hand, when the OGTT was performed after 28 weeks (late screening), a higher increase in prevalence was observed, with increases of 232 62% and 130% for the same years. In standard screening, it was notable that the age group 233 of 30 to 35 years exhibited a 75% increase in prevalence (PR 1.75; 95% CI 1.1-2.76; 234 p=0.032) (Table 5). 235

236

Table 5. Prevalence ratios of glycemic results according to year, health center and age group of each screening strategy.

	Early			Standard			Late		
	screening			screening			screening		
	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value
Gestational diabetes									
Screening year									
2019	12.3 (139 /1134)	1.00		12.3 (43/384)	1.00		9.8 (42/428)	1.00	
2020	9.4 (38/ 404)	0.76 (0.54 - 1.08)	0.127	3.4 (9/132)	0.61 (0.31 – 1.21)	0.012	7.7 (9/117)	0.78 (0.39 - 1.56)	0.594
2021	19.4 (128/ 659)	1.58 (1.27 – 1.97)	<0.001	15.3 (39/279)	1.24 (0.83 – 1.87)	0.283	16.0 (55/344)	1.62 (1.09 – 2.39)	0.015
2022	26.7 (98/ 373)	2.14 (1.70 - 2.69)	<0.001	16.5 (22/97)	2.02 (1.27 - 3.21)	0.003	14.9 (17/114)	2.30 (1.41 - 3.76)	0.001
Age group									
< 18 años	8.8 (7/ 80)	0.64 (0.31 - 1.34)	0.242	6.7 (1/ 15)	0.64 (0.09 - 4.37)	0.655	7.7 (2/ 26)	0.81 (0.20 - 3.19)	0.747
18 - 24.9	13.6 (97/716)	1.00		10.3 (30/290)	1.00		9.5 (30/311)	1.00	
25 - 29.9	13.9 (104/747)	1.02 (0.79 – 1.32)	0.835	11.9 (29/244)	1.00 (0.61 – 1.64)	0.572	12.2 (27/249)	1.12 (0.69 – 1.83)	0.642
30 - 34.9	17.9 (94/523)	1.32 (1.02 – 1.72)	0.033	17.4 (29/167)	1.75 (1.11 – 2.76)	0.032	14.3 (38/252)	1.56 (0.99 – 2.44)	0.051
35 - 39.9	20.6 (75/364)	1.52 (1.15 – 1.99)	0.003	15.9 (20/126)	1.58 (0.93 - 2.68)	0.111	14.5 (19/127)	1.55 (0.91 – 2.65)	0.109
40 - 44.9	17.6 (22/115)	1.29 (0.85 – 1.98)	0.224	6.5 (3/ 46)	0.63 (0.20 - 1.98)	0.430	11.9 (7/ 37)	1.96 (0.92 – 4.14)	0.078
45 a más	27.7 (4/15)	1.96 (0.83 – 4.64)	0.123	25 (1/4)	2.41 (0.42 - 13.7)	0.318	0.0 (0/ 1)	NC	NC
Diabetes in pregnancy*									
Screening year									
2019	0.5 (6/1140)	1.00		0.3 (1/385)	1.00		0.0 (0/428)	NC	

2020	0.7 (3/ 407)	1.40 (0.35 - 5.57)	0.633	0.0 (0/132)	NC		0.8 (1/118)	NC
2021	1.4 (9/ 668)	2.56 (0.91 - 7.16)	0.073	2.9 (5/284)	6.78 (0.79 - 57.9)	0.080	0.6 (2/346)	NC
2022	0.5 (2/ 375)	1.01 (0.20 - 5.00)	0.987	0.8 (0/97)	NC		0.0 (1/115)	NC
Age group								
< 18 años	0.0 (0/ 80)	NC		0.0 (0/ 15)	NC		0.0 (0/26)	NC
18 – 24.9	0.1 (1/717)	1.00		0.3 (1/291)	1.00		0.0 (0/311)	NC
25 - 29.9	0.6 (5/752)	4.76 (0.55 – 40.7)	0.154	0.0 (0/244)	NC		0.0 (0/249)	NC
30 - 34.9	1.0 (6/529)	8.13 (0.98 - 67.4)	0.052	1.1 (2/169)	3.44 (0.31 - 36.9)	0.311	0.0 (0/252)	NC
35 - 39.9	1.2 (4/368)	7.79 (0.87 – 69.5)	0.066	3.4 (3/129)	6.76 (0.70 - 88.8)	0.096	1.5 (3/130)	NC
40-44.9	2.6 (4/129)	22.2 (2.54 – 197.5)	0.005	0.0 (0/46)	NC		2.3 (1/38)	NC
45 a más	0.0 (0/ 15)	NC		0.0 (0/ 4)	NC		0.0 (0/ 1)	NC

240 *NO diabetes in pregnancy was the union of euglycemia and gestational diabetes

Discusión 242

Hyperglycemia in pregnancy is a condition that significantly impacts maternal and 243 244 perinatal outcomes, and its screening in primary care is essential. In this study, we found that approximately 1 in 7 pregnant women (14.9%) presents this condition, excluding 245 those with known diabetes prior to pregnancy. Of these cases, 95.5% corresponded to 246 gestational diabetes mellitus (GDM), with 60.2% identified before 24 weeks and 35.3% 247 after this period; additionally, 4.5% presented diabetes in pregnancy. 248

249 The global prevalence of subtypes of hyperglycemia in pregnancy varies according to the specific type and geographic region. According to the medical literature, hyperglycemia 250 in pregnancy affects approximately 16.9% of live births worldwide. Within this group, it 251 252 is estimated that 16.0% of cases are attributed to diabetes in pregnancy, which includes both known diabetes and previously undiagnosed cases.[19] Regarding gestational 253 diabetes, it is estimated to affect approximately 14% of pregnancies worldwide, although 254 this figure can vary depending on risk factors and diagnostic methods used.[20] For 255 instance, in Australia, the prevalence of hyperglycemia in pregnancy was reported at 256 257 13.1%, with 12.7% attributed to gestational diabetes and 0.4% to diabetes in pregnancy.[21] The study by Cosson et al. provides data on the prevalence of different 258 subtypes of hyperglycemia in pregnancy, reporting 10.8% for early diagnosed gestational 259 diabetes and 11.7% for later diagnosed gestational diabetes, while diabetes in pregnancy 260 261 and early diagnosed diabetes have a prevalence of 0.6% each.[15] Furthermore, a systematic review aimed at comparing the prevalence of GDM according to the new 262 263 IADPSG criteria versus the previous WHO criteria found that early screening increased prevalence by 60% and standard screening by 78%.[22] It is important to highlight that 264 265 more than 90% of cases of hyperglycemia during pregnancy occur in low- and middle-

19

income countries, underscoring the relevance of this condition from a public health andmaternal-infant health perspective, particularly in developing countries.[19]

268

269 Explanation of Results

Several institutions agree that pregnant women with risk factors for diabetes should 270 undergo early screening due to the high associated complication rates.[23] The IADPSG 271 guidelines, adopted by the WHO in 2013, recommended using the same cut-off points 272 between 24-28 weeks at any time during pregnancy.[24] However, it is crucial to 273 274 differentiate between two conditions that may be detected during early screening: diabetes in pregnancy (pre-gestational) and other lesser hyperglycemic states that might 275 later qualify as GDM but could merely be transient hyperglycemia during the first 276 277 trimester.

In 2015, an IADPSG panel suggested that fasting glucose values between 92 and 125 278 mg/dl should not be used for early screening, although they did not offer clear 279 alternatives.[25] This recommendation was based on an Italian study showing that only 280 45% of patients with fasting glucose greater than 92 mg/dl during the first trimester were 281 282 positive in the OGTT between 24-28 weeks, with an area under the curve (AUROC) of 0.614. [26] Similarly, a study in China recommended using a cut-off of 110 mg/dl instead 283 284 of 92 mg/dl for the first trimester, showing a slight but consistent decline in fasting 285 glucose from the first to the second trimester across the entire cohort.[27] In Simmons' clinical trial, only 67% of pregnant women with early GDM tested positive again in the 286 OGTT at 24 weeks. [16] However, a fasting glucose level greater than 92 mg/dl may be 287 288 considered a risk factor for the subsequent development of GDM, similar to pregestational body mass index. 289

20

The main goal of screening is early detection to reduce the burden of subsequent disease, and not merely to diagnose prematurely without effects on relevant clinical outcomes. It has been documented that early GDM is associated with a higher risk of perinatal mortality, neonatal hypoglycemia, and increased insulin use compared to standard screening.[28] Nevertheless, it remains unclear whether the treatment of early gestational diabetes and its intensive management can be applied to all pregnant women or only those with certain risk factors.[29,30]

297 This group of "early GDM" may represent a different range of phenotypes compared to those diagnosed after 24 weeks. A study comparing early GDM (before week 21) with 298 299 late GDM (from week 24 onwards) found lower insulin sensitivity in the early GDM group, with similar beta cell dysfunction. However, the early screening group presented 300 301 a higher pregestational body mass index (BMI).[31] It is important to discuss the impact 302 of COVID-19, which appeared in the second year of recruitment, leading to a decrease in 303 screening tests. However, when conditions improved, the program continued to follow 304 the same algorithm, resulting in a notable increase in the prevalence of hyperglycemia, 305 reaching up to 60% compared to 2019. Other studies have reported an increase ranging from 14% to 34%. [32,33] A possible explanation for this increase could be related to the 306 307 rise in pregestational weight and gestational weight gain, which is linked to lifestyle changes such as reduced physical activity and increased stress, as well as changes in 308 healthcare access and service utilization.[34–36] 309

310 Research Recommendations

Longitudinal studies or cost-effectiveness analyses are needed to evaluate the impact on perinatal outcomes for patients diagnosed with early gestational diabetes (GDM) or through standard screening to determine whether this trend is also observed in Latino populations. Furthermore, greater clarity is needed on whether early screening could be

21

implemented universally or based on risk factors (such as obesity or previous history of 315 316 GDM). It is essential to define the exact timing during the first trimester, considering the physiological changes in pregnant women (before or after 16 weeks) or to use less strict 317 diagnostic glycemic thresholds (recommended 110 mg/dl fasting). Regarding the 318 diagnostic method, the oral glucose tolerance test (OGTT) and its variants are universally 319 accepted. However, they are not easily applied in logistical terms for screening. 320 321 Alternative diagnostic methods are being explored that offer better feasibility, such as hemoglobin A1c with a cut-off of 5.9%.[37] Additionally, multiple biological markers, 322 such as C-reactive protein, adiponectin, and tumor necrosis factor, are being evaluated 323 either in isolation or in combination with clinical variables as alternatives to the 324 OGTT.[38] 325

326 Limitations and Strengths

Several limitations were identified in the present study. The cut-off points used for early 327 gestational diabetes (GDM) lack long-term studies to support their impact and are based 328 on IADPSG criteria. This may lead to an overestimation of GDM prevalence. 329 Nonetheless, the World Health Organization (WHO) continues to recommend their use. 330 331 Furthermore, the database did not include other variables that could explain differences 332 in diagnostic prevalence, such as pregestational body mass index or previous history of 333 gestational diabetes. However, we have sufficient statistical power to estimate differences between age groups. The COVID-19 pandemic also affected data collection and the 334 performance of tests. Nevertheless, the tests that were conducted adhered to strict 335 biosafety protocols. It is possible that GDM between 24 and 28 weeks is 336 underrepresented, as the OGTT was not repeated for patients who tested negative in the 337 early screening. Among the strengths of this study, we highlight the sample size, which 338

22

allows for prevalence estimates with an accuracy of 1.3%. Additionally, the OGTT wasused, recognized as the gold standard for diagnosing gestational diabetes.

341

342 **Conclusion**

- 343 In pregnant women from four primary care centers in South Lima, it was found that one
- in seven (14.9%) presented hyperglycemia in pregnancy. GDM was 14.2%, and DIP was
- 0.7%. Early screening showed the highest proportion of GDM compared to standard or
- 346 late screening. No differences in the prevalence of diabetes in pregnancy were found
- 347 between the groups. Longitudinal studies are needed to determine whether this higher
- 348 prevalence associated with early screening has repercussions on maternal-perinatal
- 349 complications and whether it requires any form of treatment.

Bibliographics references 350

351 352 353 354	1.	International Diabetes Federation. IDF Diabetes Atlas 10th edition. Bruselas, Béglica.; 2021. Available: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
355 356 357	2.	Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al. Hyperglycaemia and risk of adverse perinatal outcomes : systematic review and meta- analysis. BMJ. 2016;354: i4694. doi:10.1136/bmj.i4694
358 359 360	3.	Poolsup N, Suksomboon N, Amin M. Effect of Treatment of Gestational Diabetes Mellitus : A Systematic Review and Meta-Analysis. PLoS One. 2014;9: 1–9. doi:10.1371/journal.pone.0092485
361 362	4.	Ferrara A. Increasing Prevalence of Gestational Diabetes Mellitus. A public health perspective. Diabetes Care. 2007;30: S141-146. doi:10.2337/dc07-s206
363 364 365 366	5.	Instituto Nacional de Estadística e Informática. "Perú: Encuesta Demográfica y de Salud Familiar 2023 - Nacional y Departamental. Lima, Perú; 2024. Available: https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1950/libr o.pdf
367 368 369	6.	Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. Interventions to reduce or prevent obesity in pregnant women : a systematic review. Health Technol Assess (Rockv). 2012;16. doi:10.3310/hta16310
370 371 372	7.	Behboudi-Gandevani S, Amiri M, Yarandi RB, Tehrani FR. The impact of diagnostic criteria for gestational diabetes on its prevalence : a systematic review and meta - analysis. Diabetol Metab Syndr. 2019;11: 11. doi:10.1186/s13098-019-0406-1
373 374 375	8.	Chen PY, Finkelstein EA, Ng MJ, Yap F, Yeo GSH, Rajadurai VS, et al. Incremental Cost-Effectiveness Analysis of Gestational Diabetes Mellitus Screening Strategies in Singapore. Asia Pac J Public Health. 2016;28: 15–25. doi:10.1177/1010539515612908
376 377 378 379	9.	Werner E, Pettker C, Zuckerwise L, Reel M, Funai E, Henderson J, et al. Screening for Gestational Diabetes Mellitus: Are the Criteria Proposed by the International Association of the Diabetes and Pregnancy Study Groups Cost-Effective? Diabetes Care. 2012;35: 529–35. doi:10.2337/dc11-1643
380 381 382 383 384	10.	Duran A, Śaenz S, Torrejon MJ, Bordí U E, Del Valle L, Galindo M, et al. Introduction of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: The St. Carlos gestationaldiabetes study. Diabetes Care. 2014;37: 2442–2450. doi:10.2337/dc14-0179
385 386	11.	Hod M, Kapur A, Sacks D, Hadar E, Agarwal M, Di Renzo G, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes

387 388		mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynecol Obstet. 2015;131: S173-211. doi:10.1016/S0020-7292(15)30033-3
389 390 391 392	12.	Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216: 110-120.e6. doi:10.1016/J.AJOG.2016.09.076
393 394 395	13.	Ye Y, Xiong Y, Zhou Q, Xiao X, Li X. Early-Pregnancy Intermediate Hyperglycemia and Adverse Pregnancy Outcomes Among Women Without Gestational Diabetes. J Clin Endocrinol Metab. 2021;107: e1541. doi:10.1210/CLINEM/DGAB841
396 397 398 399	14.	Regnault N, Lebreton E, Tang L, Fosse-Edorh S, Barry Y, Olié V, et al. Maternal and neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy: a nationwide cross-sectional study of 695,912 deliveries in France in 2018. Diabetologia. 2024;67: 516–527. doi:10.1007/S00125-023-06066-4
400 401 402	15.	Cosson E, Bentounes SA, Nachetergaele C, Berkane N, Pinto S, Sal M, et al. Prognosis Associated with Sub-Types of Hyperglycaemia in Pregnancy. J Clin Med. 2021;10. doi:10.3390/JCM10173904
403 404 405 406 407	16.	Simmons D, Immanuel J, Hague WM, Teede H, Nolan CJ, Peek MJ, et al. Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. New England Journal of Medicine. 2023;388: 2132–2144. doi:10.1056/NEJMOA2214956/SUPPL_FILE/NEJMOA2214956_DATA- SHARING.PDF
408 409 410	17.	Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: differences between the current international diagnostic criteria and implications of switching to IADPSG. J Diabetes Complications. 2015;29: 544–549. doi:10.1016/J.JDIACOMP.2015.03.006
411 412 413 414	18.	Larrabure-Torrealva GT, Martinez S, Luque-Fernandez MA, Sanchez SE, Mascaro PA, Ingar H, et al. Prevalence and risk factors of gestational diabetes mellitus : findings from a universal screening feasibility program in Lima , Peru. BMC Pregnancy Childbirth. 2018;18: 303. doi:https://doi.org/10.1186/s12884-018-1904-0
415 416 417	19.	Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103: 176–185. doi:10.1016/J.DIABRES.2013.11.003
418 419 420	20.	Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, et al. Epidemiology and management of gestational diabetes. Lancet. 2024;404: 175–192. doi:10.1016/S0140-6736(24)00825-0
421 422 423	21.	Moses RG, Wong VCK, Lambert K, Morris GJ, San Gil F. The prevalence of hyperglycaemia in pregnancy in Australia. Aust N Z J Obstet Gynaecol. 2016;56: 341–345. doi:10.1111/AJO.12447
424 425	22.	Saeedi M, Cao Y, Fadl H, Gustafson H, Simmons D. Increasing prevalence of gestational diabetes mellitus when implementing the IADPSG criteria: A systematic

426 427		review and meta-analysis. Diabetes Res Clin Pract. 2021;172: 108642. doi:10.1016/J.DIABRES.2020.108642
428 429 430 431	23.	Malaza N, Masete M, Adam S, Dias S, Nyawo T, Pheiffer C. A Systematic Review to Compare Adverse Pregnancy Outcomes in Women with Pregestational Diabetes and Gestational Diabetes. Int J Environ Res Public Health. 2022;19: 10846. doi:10.3390/IJERPH191710846/S1
432 433 434	24.	Organización Panamericana de la Salud. Criterios diagnósticos y clasificación de la hiperglucemia detectada por primera vez en el embarazo. 2016; 6. Available: https://iris.paho.org/handle/10665.2/27870
435 436 437	25.	McIntyre HD, Sacks DA, Barbour LA, Feig DS, Catalano PM, Damm P, et al. Issues With the Diagnosis and Classification of Hyperglycemia in Early Pregnancy. Diabetes Care. 2016;39: 53–54. doi:10.2337/DC15-1887
438 439 440 441	26.	Corrado F, D'Anna R, Cannata ML, Interdonato ML, Pintaudi B, Di Benedetto A. Correspondence between first-trimester fasting glycaemia, and oral glucose tolerance test in gestational diabetes diagnosis. Diabetes Metab. 2012;38: 458–461. doi:10.1016/J.DIABET.2012.03.006
442 443 444	27.	Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al. Evaluation of the Value of Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes Mellitus in China. Diabetes Care. 2013;36: 586. doi:10.2337/DC12-1157
445 446 447	28.	Immanuel J, Simmons D. Screening and Treatment for Early-Onset Gestational Diabetes Mellitus: a Systematic Review and Meta-analysis. Curr Diab Rep. 2017;17. doi:10.1007/S11892-017-0943-7
448 449 450 451	29.	Falavigna M, Schmidt MI, Trujillo J, Alves LF, Wendland ER, Torloni MR, et al. Effectiveness of gestational diabetes treatment: A systematic review with quality of evidence assessment. Diabetes Res Clin Pract. 2012;98: 396–405. doi:10.1016/j.diabres.2012.09.002
452 453 454 455	30.	Behboudi-Gandevani S, Bidhendi-Yarandi R, Panahi MH, Vaismoradi M. The Effect of Mild Gestational Diabetes Mellitus Treatment on Adverse Pregnancy Outcomes: A Systemic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;12: 640004. doi:10.3389/FENDO.2021.640004/BIBTEX
456 457 458 459 460	31.	Bozkurt L, Göbl CS, Pfligl L, Leitner K, Bancher-Todesca D, Luger A, et al. Pathophysiological Characteristics and Effects of Obesity in Women With Early and Late Manifestation of Gestational Diabetes Diagnosed by the International Association of Diabetes and Pregnancy Study Groups Criteria. J Clin Endocrinol Metab. 2015;100: 1113–1120. doi:10.1210/JC.2014-4055
461 462 463	32.	Auger N, Wei SQ, Dayan N, Ukah U V., Quach C, Lewin A, et al. Impact of Covid-19 on rates of gestational diabetes in a North American pandemic epicenter. Acta Diabetol. 2023;60: 257–264. doi:10.1007/S00592-022-02000-Z

464 465 466	33.	Zanardo V, Tortora D, Sandri A, Severino L, Mesirca P, Straface G. COVID-19 pandemic: Impact on gestational diabetes mellitus prevalence. Diabetes Res Clin Pract. 2022;183. doi:10.1016/j.diabres.2021.109149
467 468 469 470	34.	Rhou YJJ, Elhindi J, Melov SJ, Cheung NW, Pasupathy D. Indirect effects of the COVID-19 pandemic on risk of gestational diabetes and factors contributing to increased risk in a multiethnic population: a retrospective cohort study. BMC Pregnancy Childbirth. 2023;23: 1–10. doi:10.1186/S12884-023-05659-6/TABLES/4
471 472 473	35.	Nour TY, Altintaş KH. Effect of the COVID-19 pandemic on obesity and it is risk factors: a systematic review. BMC Public Health. 2023;23: 1–24. doi:10.1186/S12889-023-15833-2/FIGURES/1
474 475 476	36.	Pinedo-Soria A, Pasco-Ramírez F, Samir Cubas W. Ganancia de peso durante el confinamiento por la COVID-19 en la población peruana. Revista Médica Herediana. 2022;33: 72–73. doi:10.20453/RMH.V33I1.4172
477 478 479 480	37.	Hughes RCE, Moore MP, Gullam JE, Mohamed K, Rowan J. An Early Pregnancy HbA1c ≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care. 2014;37: 2953–2959. doi:10.2337/DC14-1312
481 482 483	38.	Huhn EA, Rossi SW, Hoesli I, Göbl CS. Controversies in Screening and Diagnostic Criteria for Gestational Diabetes in Early and Late Pregnancy. Front Endocrinol (Lausanne). 2018;9: 411579. doi:10.3389/FENDO.2018.00696/BIBTEX
484		
10E		

Supplementary tables 486

- Table S1. Results of basal glycemia, 60 minutes and 120 minutes of OGTT according 488
- to clinical characteristics in pregnant women 489
- Table S2. Characteristics of patients with gestational diabetes 490
- 491
- Tabla S3. Carácterísticas de las pacientescon Diabetes pregestacional. 492

